6.24
Vanda Pharmaceuticals Inc stock is currently priced at $6.24, with a 24-hour trading volume of 1.12M.
It has seen a -4.00% decreased in the last 24 hours and a +21.64% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $6.48 pivot point. If it approaches the $6.22 support level, significant changes may occur.
Previous Close:
$6.50
Open:
$6.46
24h Volume:
1.12M
Market Cap:
$363.16M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
23.11
EPS:
0.27
Net Cash Flow:
$12.42M
1W Performance:
+1.96%
1M Performance:
+21.64%
6M Performance:
+62.08%
1Y Performance:
-0.48%
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 Pennsylvania Avenue NW, Suite 300E, Washington
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
May-12-21 | Initiated | BofA Securities | Buy |
Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
Jul-25-19 | Downgrade | Stifel | Buy → Hold |
Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Dec-04-18 | Reiterated | Jefferies | Buy |
Nov-08-18 | Resumed | Jefferies | Buy |
Sep-21-18 | Resumed | Oppenheimer | Outperform |
May-23-18 | Initiated | Citigroup | Buy |
Jan-19-18 | Initiated | Seaport Global Securities | Buy |
Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
Jun-27-17 | Resumed | Piper Jaffray | Overweight |
May-26-17 | Initiated | H.C. Wainwright | Buy |
Apr-12-17 | Initiated | Oppenheimer | Outperform |
Nov-09-16 | Initiated | Aegis Capital | Buy |
Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Insider Selling: Polymeropoulos Mihael Hristos, Vanda Pharmaceuticals Inc [VNDA] President and CEO divested ... - Knox Daily
Knox Daily
A Tale of Resilience: Vanda Pharmaceuticals Inc Amid Stock Market Turbulence - The InvestChronicle
The InvestChronicle
Vanda Pharmaceuticals Shares Rise 11% After New Buyout Offer From Future Pak - MarketWatch
MarketWatch
Vanda Pharmaceuticals stock gains as Future Pak raises offer to $8.50-$9 a share - Seeking Alpha
Seeking Alpha
Financial Snapshot: Analyzing Vanda Pharmaceuticals Inc (VNDA)'s Key Ratio Metrics – DWinneX - The Dwinnex
The Dwinnex
Are Vanda Pharmaceuticals Inc (VNDA) shares a good deal now? – US Post News - US Post News
US Post News
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Vanda Pharmaceuticals Inc (VNDA) Revenue 2024
VNDA reported a revenue (TTM) of $192.64 million for the quarter ending December 31, 2023, a -24.27% decline year-over-year.
Vanda Pharmaceuticals Inc (VNDA) Net Income 2024
VNDA net income (TTM) was $2.51 million for the quarter ending December 31, 2023, a -60.02% decrease year-over-year.
Vanda Pharmaceuticals Inc (VNDA) Cash Flow 2024
VNDA recorded a free cash flow (TTM) of $12.42 million for the quarter ending December 31, 2023, a -60.33% decrease year-over-year.
Vanda Pharmaceuticals Inc (VNDA) Earnings per Share 2024
VNDA earnings per share (TTM) was $0.0524 for the quarter ending December 31, 2023, a -56.33% decline year-over-year.
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Cap:
|
Volume (24h):